Category: HeartWare International Inc.
HeartWare International's preliminary sales numbers for the 4th quarter beat expectations as it launches a thoracotomy trial for its implantable heart pump.
Thoratec's 3rd-quarter earnings plunge nearly 85% as sales decline more than 16%, raising fears that the left ventricular-assist device market is in a slump that could persist into 2015.
Thoratec (NSDQ:THOR) yesterday said its 3rd-quarter profits plunged some 85%, missing forecasts, and dimmed its outlook for the rest of the year.
HeartWare posts narrowed 3rd-quarter losses thanks to increased sales of its implantable heart pumps in the U.S.
HeartWare International (NSDQ:HTWR) yesterday reported narrowed 3rd-quarter losses and significantly higher revenues, boosted by a 39% jump in U.S. sales of its implantable heart pumps.
HeartWare International names Dr. Katrin Leadley to be its new chief medical officer following the retirement of Dr. David Hathaway.
, eLux Medical
, HeartWare International Inc.
, NxStage Medical Inc.
, Revolutions Medical Corp.
, Terumo Corp.
, X2 Biosystems
, AngioDynamics Inc.
A voluntary recall initiated yesterday pushes HeartWare shares down today, despite 2nd-quarter result that crushed expectations on Wall Street.
UPDATED July 31, 2014 with additional comment on recall.
FDA regulators publish a formal warning against HeartWare, for which the company had advised shareholders to be on the lookout.
FDA inspectors finally revealed the anticipated warning letter against Massachusetts-based medical device maker HeartWare (NSDQ:HTWR), chiding the company for manufacturing violations.
Here's a look at some of the top regulatory stories for medical device companies this week: Medical device recalls for May 2014; Diabetes: Medtronic wins CE Mark for MiniMed Duo; Diabetes: DexCom wins FDA approval for professional glucose monitor; Unique Device Identifiers: 4 tips for compliance; HeartWare reveals FDA warning letter.
Class I recalls: 9
Class II recalls: 137